Conv. Plasma
Nigella Sativa
Peg.. Lambda

All ivermectin studies
Meta analysis
Home COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Hospitalization 52% Improvement Relative Risk Recovery time 43% Mortality 51% late Ventilation 63% late Hospitalization time 30% late Mebendazole  Galal et al.  EARLY TREATMENT Is early treatment with mebendazole beneficial for COVID-19? Retrospective 185 patients in Egypt (June - August 2020) Faster recovery with mebendazole (p=0.001) Galal et al., Advances in Virology, Dec 2022 Favors mebendazole Favors control

The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study

Galal et al., Advances in Virology, doi:10.1155/2022/3014686
Dec 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 157 inpatients and 185 outpatients in Egypt, showing improved recovery with mebendazole. For outpatients, the trreatment group was younger (40 vs. 48). Mebendazole was offered to patients when ivermectin/HCQ were unavailable.
risk of hospitalization, 51.6% lower, RR 0.48, p = 0.33, treatment 3 of 94 (3.2%), control 6 of 91 (6.6%), NNT 29.
recovery time, 42.9% lower, relative time 0.57, p < 0.001, treatment 94, control 91.
risk of death, 50.9% lower, RR 0.49, p = 0.35, treatment 3 of 68 (4.4%), control 8 of 89 (9.0%), NNT 22, late treatment result.
risk of mechanical ventilation, 62.6% lower, RR 0.37, p = 0.30, treatment 2 of 68 (2.9%), control 7 of 89 (7.9%), NNT 20, late treatment result.
hospitalization time, 30.0% lower, relative time 0.70, p < 0.001, treatment 68, control 89, late treatment result.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Galal et al., 10 Dec 2022, retrospective, Egypt, peer-reviewed, 11 authors, study period 1 June, 2020 - 30 August, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Hindawi Advances in Virology Volume 2022, Article ID 3014686, 6 pages Research Article The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study Mostafa W. Galal,1 Mahmoud Ahmed,2 Yanqiu Shao,3,4 Chao Xing,4,5 Wael Ali,6 Abd Elhamid Baly,7 Abdallah Elfky,8 Khaled Amer,9 John Schoggins,10 Hesham A. Sadek ,11,2 and Zeinab N. Gobara 7 1 School of Medicine, Aim Shams University, Cairo, Egypt Department of Internal Medicine Cardiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 3 Department of Statistical Science, Southern Methodist University, Dallas, TX 75275, USA 4 Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 5 McDermott Center for Human Growth and Development and Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 6 Egyptian Center for Research in Regenerative Medicine, Cairo, Egypt 7 Department of Clinical Pathology, Cura El-Nasr Hospitals, Cairo, Egypt 8 Department of Radiology, Cura El-Nasr Hospitals, Helwan university, Cairo, Egypt 9 Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 10 Epartments Microbiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 11 Departments Biophysics and Molecular Biology and Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA 2 Correspondence should be addressed to Zeinab N. Gobara; Received 5 February 2022; Revised 16 May 2022; Accepted 26 August 2022; Published 10 December 2022 Academic Editor: Shih-Chao Lin Copyright © 2022 Mostafa W. Galal et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. An in-silico screen identifed mebendazole with potential antiviral activity that could be a repurposed drug against SARSCoV-2. Mebendazole is a well-tolerated and cheap antihelminthic agent that is readily available worldwide and thus could be a therapeutic tool in the fght against COVID-19. Methods. Tis is an observational retrospective study of PCR-confrmed COVID-19 patients who received mebendazole with the intention-to-treat. Te study included an inpatient cohort (157 inpatients) and an outpatient cohort (185 outpatients). Of the 157 inpatients and 185 outpatients, 68 (43.3%) and 94 (50.8%) received mebendazole, respectively. Patients who presented within the same timeframe but did not receive mebendazole were used as controls. Patients received standard-ofcare treatment including remdesivir, dexamethasone, and anticoagulants as deemed necessary by the treating physician. Te following clinical outcomes were evaluated: for the inpatient cohort, length of stay (LOS) at the hospital, need for ventilation (combined invasive and noninvasive), and mortality; for the outpatient cohort, time to symptom resolution, need for hospitalization, and mortality. Results. For the inpatient cohort, the median age did not difer between the treatment and control groups; 62 (56, 67) vs. 62 (56, 68), P, and there was a comparable proportion of males in both groups; 43 (63%) vs. 55 (62%), P � 0.85. Te hospital LOS was 3.5 days shorter in the treatment group compared to the..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop